In this edition of Investor Eye, Medtech Insight meets with Howard Rowe, managing director and head of health care at Hayfin Capital Management, a $17bn international asset management firm headquartered in London.

Encouraged by its solid sales performance in the first half of this year, UK aesthetics company Sinclair Pharma is optimistic it can close out 2017 with a small profit. The firm's H1 revenues were boosted by continued growth in key markets, leading to a 16% top-line growth.

Sinclair Pharma has gained access to the world’s largest aesthetics market by enlisting Thermigen as the exclusive US distributor of Silhouette InstaLift, a non-surgical alternative to facelifts.